嵌合抗原受体T细胞联合免疫检查点抑制剂治疗恶性肿瘤的研究进展

Advances of chimeric antigen receptor T-cell immunotherapy combined with immune checkpoint inhibitors in malignancies therapy

近年来,嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)治疗在恶性肿瘤治疗中取得了较多成果,尤其在血液肿瘤治疗方面有所突破,实体瘤治疗研究前景较为广阔,有望成为更多复发难治性肿瘤患者的选择。免疫检查点抑制剂疗法在肿瘤治疗中同样具有疗效,如肝癌、难治性霍奇金淋巴瘤等多种恶性肿瘤,为晚期肿瘤患者带来了希望。但是上述两种治疗方法均存在不同程度的局限性。CAR-T联合免疫检查点抑制剂会削弱肿瘤微环境的免疫抑制作用,提高CAR-T治疗的有效率,延长生存期。本文旨在对CAR-T细胞和免疫检查点抑制剂治疗及二者联合应用的研究进展予以综述。

Recent years, chimeric antigen receptor T-cell （CAR-T） therapy has made great strides in enabling better treatment of malignant tumors, especially hematological tumors, as well as increasing the research prospects of potential solid tumor therapies. Consequently, CAR-T therapy is expected to become the selected treatment for patients with relapsed and refractory tumors. Immune check- point inhibitors also have certain curative effects in the treatment of cancers, such as liver cancer, refractory Hodgkin＇s lymphoma, and other malignant tumors, which brings promise to patients with advanced cancer. However, both treatments have different degrees of limitations. Recent clinical trials suggest that combined immune checkpoint inhibitors impair the immunosuppressive effects of the tumor microenvironment, increase the efficacy of CAR-T therapy, and prolong the survival. This article will review the research progress on the combination of CAR-T immunotherapy and immune checkpoint inhibitors in malignancies theray.